Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW.

Arthritis Rheumatol. 2014 Feb;66(2):480. doi: 10.1002/art.38251. No abstract available.

2.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al.

Bonroy C, Verfaillie C, De Witte E, De Keyser F.

Arthritis Rheumatol. 2014 Feb;66(2):479-80. doi: 10.1002/art.38252. No abstract available.

3.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups..

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

4.

Cytokine-producing T cells in systemic lupus erythematosus: comment on the article by Akahoshi et al.

Reuss-Borst MA, Geyer A, Berner B.

Arthritis Rheum. 2000 Mar;43(3):711-2. No abstract available.

5.

Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: comment on the article by Efthimiou et al.

Zhang HL, Qin GX, Fan ZY, Wu J.

Arthritis Rheum. 2011 Jan;63(1):309; author reply 309-10. doi: 10.1002/art.27745. No abstract available.

6.

Thrombocytopenia as a prognostic factor in Hispanic patients with systemic lupus erythematosus: comment on the article by Fernández et al.

Drenkard C, Villa AR.

Arthritis Rheum. 2007 Aug;56(8):2811-2; author reply 2812. No abstract available.

7.

Corticosteroids in preventing severe lupus flares: do all patients have the same risk? Comment on the article by Tseng et al.

Callejas-Rubio JL, Rios-Fernández R, Tomás-Jiménez C, Ortego-Centeno N.

Arthritis Rheum. 2007 Jun;56(6):2098-9; author reply 2099. No abstract available.

8.

Entry criteria influence conclusions about rates of flare in lupus pregnancy: comment on the article by Petri et al.

Lockshin MD.

Arthritis Rheum. 1992 Jul;35(7):846-7. No abstract available.

PMID:
1622430
9.

[Function of flow cytometry on the dosage of antibodies against double stranded DNA in systemic lupus erythematosus].

Ferrero PV, Drenkard C, Collino C, Cabral MJ, Gamron S, Barberis G, Onetti CM, Menso de Ezcurra EM.

Rev Alerg Mex. 2005 Jan-Feb;52(1):7-17. Spanish.

PMID:
15957468
10.

[Antihistones antibodies in systemic lupus erythematosus, comparison of three assays: Elisa, dot blot and immunoblot].

Ghedira I, Landolsi H, Mankai A, Fabien N, Jeddi M.

Pathol Biol (Paris). 2006 Apr;54(3):148-54. French.

PMID:
16169158
11.

Bullous systemic lupus erythematosus and lupus nephritis in a 10 year old boy.

Vijayalakshmi AM, Jayavardhana A.

Indian Pediatr. 2007 Nov;44(11):861-3.

12.
13.
14.

Binding of anti-double stranded (ds) DNA-positive sera to denatured (d) DNA and synthetic poly[dA-dT] x poly[dA-dT] double stranded copolymer in an ELISA format.

Batinić D, Bozićević M, Krstulović A, Bosnić D, Sentić M, Markeljević J, Malenica B, Cikes N, Marusić M.

Eur J Clin Chem Clin Biochem. 1996 Apr;34(4):343-7.

PMID:
8704051
15.

Triplets with systemic lupus erythematosus.

Kamat SS, Pepmueller PH, Moore TL.

Arthritis Rheum. 2003 Nov;48(11):3176-80.

16.

Association between autoantibodies and neuropsychiatric manifestations of autoimmune disease: comment on the article by Lauvsnes et al.

Kivity S, Shoenfeld Y.

Arthritis Rheumatol. 2015 Jun;67(6):1683. doi: 10.1002/art.39077. No abstract available.

17.

Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis.

Abdwani R, Rizvi SG, El-Nour I.

Lupus. 2008 Jul;17(7):683-6. doi: 10.1177/0961203307087611.

PMID:
18625643
18.

Comment on the article by Stafford-Brady et al.

Merry P, Acheson JF, Asherson RA.

Arthritis Rheum. 1989 Aug;32(8):1053-4. No abstract available.

PMID:
2818741
19.

Clinical features and outcome of systemic lupus erythematosus.

Agarwal I, Kumar TS, Ranjini K, Kirubakaran C, Danda D.

Indian Pediatr. 2009 Aug;46(8):711-5.

20.

Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.

Ramos-Casals M, Díaz-Lagares C, Khamashta MA.

Arthritis Rheum. 2009 Sep 15;61(9):1281-2. doi: 10.1002/art.24726. No abstract available.

Items per page

Supplemental Content

Support Center